If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.30
Bid: 4.10
Ask: 4.50
Change: 0.00 (0.00%)
Spread: 0.40 (9.756%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4.30
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Auditor

28 Sep 2022 08:46

RNS Number : 9772A
Eden Research plc
28 September 2022
 

28 September 2022

Eden Research Plc

("Eden" or "Company")

Change of Auditor

Eden Research plc (AIM: EDEN; OTCQB: EDNSF), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, today announces that, following a competitive and comprehensive tender process, PKF Littlejohn LLP ("PKF") has been appointed as the Company's auditor for the year ending 31 December 2022. The Company intends to put the appointment of PKF as auditor to a vote of shareholders at the Company's next Annual General Meeting.

Following the tender process and the decision to appoint PKF, KPMG UK LLP ("KPMG") has resigned. The Board wishes to take this opportunity to extend appreciation to KPMG for its services rendered to the Company.

As required by section 519 of the Companies Act 2006, KPMG has deposited a statement with the Company confirming that there are no circumstances in connection with its resignation as auditor that should be brought to the attention of the Company's shareholders and the reason for their resignation was as a result of its fees no longer being acceptable to the Company.

 

For further information, contact:

 

Eden Research plc

Sean Smith

Alex Abrey

 

www.edenresearch.com

01285 359 555

Cenkos Securities (NOMAD and broker)

Giles Balleny / Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

020 7397 8900

Hawthorn Advisors

Stephen Atkinson

Victoria Ainsworth

 

eden@hawthornadvisors.com

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. 

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market: 

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz™ is a bio-nematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services. 

 

For more information about Eden, please visit: www.edenresearch.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPEAXNPALSAEEA
Date   Source Headline
29th Jun 202212:18 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:12 amRNSNotice of AGM & Publication of Annual Report
7th Jun 20227:00 amRNSInvestor Meet Company: 2021 Results Presentation
31st May 202210:29 amRNSDirector/PDMR Shareholding
31st May 20227:00 amRNSPreliminary results
16th May 20225:05 pmRNSHolding(s) in Company
10th May 20227:00 amRNSRegulatory update
2nd Mar 20227:00 amRNSTrading Update
2nd Dec 20217:00 amRNSNew Major Crop Use for Mevalone in France
20th Oct 20217:00 amRNSAdmission to the US OTC Market
28th Sep 20217:00 amRNSHalf Yearly Report
24th Sep 202112:32 pmRNSNotice of General Meeting
1st Sep 20217:00 amRNSIssuing of Annual Report & Notice of GM
26th Aug 20217:00 amRNSNew label extension for biofungicide in Portugal
28th Jul 20212:53 pmRNSDirector/PDMR Shareholding
27th Jul 20217:00 amRNSAgreement with Sipcam in North Africa
23rd Jul 20217:00 amRNSGrant of Awards under Long-Term Incentive Plan
12th Jul 20214:10 pmRNSHolding(s) in Company
5th Jul 20217:00 amRNSRegulatory approvals
1st Jul 202112:19 pmRNSPublication of Report and Accounts
30th Jun 202112:03 pmRNSResult of AGM
30th Jun 20217:00 amRNSPreliminary Results for Year Ended 31 Dec 2020
29th Jun 202111:27 amRNSVirtual Investor Conference – Link for webinar
7th Jun 20213:28 pmRNSNotice of AGM, investor conference & Accounts
12th May 20217:00 amRNSMilestone Agreement signed with Corteva
10th May 20217:00 amRNSRegulatory approval for Cedroz™ in Italy
1st Apr 20217:00 amRNSGrant of Awards under Long-Term Incentive Plan
31st Mar 20217:00 amRNSNew authorisations for bio-fungicide in Spain
29th Mar 20211:27 pmRNSHolding(s) in Company
19th Feb 20214:41 pmRNSSecond Price Monitoring Extn
19th Feb 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20212:05 pmRNSSecond Price Monitoring Extn
19th Feb 20212:01 pmRNSPrice Monitoring Extension
11th Feb 20219:05 amRNSSecond Price Monitoring Extn
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:00 amRNSYear end trading update
5th Jan 20217:00 amRNSGreen Economy Mark
2nd Nov 20207:00 amRNSEden partners with M H Poskitt
13th Oct 20207:00 amRNSChange of Registered Office
29th Sep 20207:00 amRNSHalf-year Report
17th Sep 20207:00 amRNSNew authorisations for Cedroz™ and Mevalone®
15th Sep 20207:00 amRNSKey patent granted for Eden’s Sustaine technology
1st Sep 20207:00 amRNSRegulatory approval for Cedroz™ in Spain
25th Aug 20207:00 amRNSNew authorisation for bio-fungicide in Australia
5th Aug 20207:00 amRNSNew authorisation for Cedroz™ in Greece
10th Jul 20207:00 amRNSAppointment of Global Head of Biology and Dev
1st Jul 20207:00 amRNSNew office and laboratory in Oxfordshire
25th Jun 20207:00 amRNSPatents granted in the United States
24th Jun 202012:20 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.